<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="493">
  <stage>Registered</stage>
  <submitdate>9/11/2004</submitdate>
  <approvaldate>9/11/2004</approvaldate>
  <nctid>NCT00096408</nctid>
  <trial_identification>
    <studytitle>Laparoscopic Approach to Cancer of the Endometrium</studytitle>
    <scientifictitle>LACE - Laparoscopic Approach to Cancer of the Endometrium: An International Multicenter Randomized Phase 3 Clinical Trial</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>LACE001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Endometrial Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Total Abdominal Hysterectomy
Treatment: surgery - Total Laparoscopic Hysterectomy

Active Comparator: 1 - Total Abdominal Hysterectomy

Experimental: 2 - Total Laparoscopic Hysterectomy


Treatment: surgery: Total Abdominal Hysterectomy
For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.

Treatment: surgery: Total Laparoscopic Hysterectomy
The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Disease free survival</outcome>
      <timepoint>4.5 years from surgery</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Intra/Peri/Post-operative and long-term morbidity</outcome>
      <timepoint>30 days from surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patterns of recurrence</outcome>
      <timepoint>4.5 years from surgery</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain and analgesia</outcome>
      <timepoint>1 week, 1 month, 3 months and 6 months postoperative.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life</outcome>
      <timepoint>Measured at baseline, then again 1 week, 6 weeks, 3 months and 6 months postoperatively.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients who may be included for this study must have the following:

          -  Histologically confirmed primary endometrioid adenocarcinoma of the endometrium;

          -  Clinical stage I disease;

          -  ECOG Performance status of 0-1;

          -  Signed written informed consent;

          -  Females, aged 18 years or older.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients will be excluded from participating from the study if they have any of the
        following:

          -  Other histologic type than endometrioid adenocarcinoma of the endometrium;

          -  Clinically advanced disease (stages II-IV);

          -  Uterine size larger than 10 weeks gestation;

          -  Estimated life expectancy of less than 6 months;

          -  Enlarged aortic lymph nodes;

          -  Unfit for Surgery: serious concomitant systemic disorders incompatible with the study
             (at the discretion of the investigator);

          -  Patient compliance and geographic proximity that does not allow adequate follow-up;

          -  Unfit to complete QoL measurements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>760</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Newcastle Private Hospital - New Lambton Heights</hospital>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>Royal Hospital for Women - Randwick</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>The Wesley Hospital - Auchenflower</hospital>
    <hospital>Greenslopes Private Hospital - Greenslopes</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Herston</hospital>
    <hospital>Mater Adult Public Hospital - South Brisbane</hospital>
    <hospital>Mater Misericordiae Hospital Townsville - Townsville</hospital>
    <hospital>Townsville Hospital - Townsville</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Royal Women's Hospital - Carlton</hospital>
    <hospital>Monash Medical Centre - East Bentleigh</hospital>
    <hospital>Cabrini Health - Malvern</hospital>
    <hospital>King Edward Memorial Hospital for Women - Perth</hospital>
    <hospital>St John of God Hospital - Subiaco</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2305 - New Lambton Heights</postcode>
    <postcode>2305 - New Lambton</postcode>
    <postcode>2031 - Randwick</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2050 - Westmead</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4120 - Greenslopes</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>4810 - Townsville</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3168 - Carlton</postcode>
    <postcode>3204 - East Bentleigh</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>6008 - Perth</postcode>
    <postcode>6904 - Subiaco</postcode>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Pokfulam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Canterbury</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Edinburgh</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Queensland Centre for Gynaecological Cancer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Tyco Healthcare Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Gynetech</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Queensland Government - Smart Health Research Grant</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council Queensland</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council Victoria</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council Western Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to assess disease-free survival at 4.5 years
      postoperatively for women with apparent Stage 1 endometrial cancer, comparing patients who
      are randomised to receive Total Laparoscopic Hysterectomy (TLH) and patients who are
      randomised to receive Total Abdominal Hysterectomy (TAH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00096408</trialwebsite>
    <publication>Janda M, Gebski V, Forder P, Jackson D, Williams G, Obermair A; LACE Trial Committee. Total laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized controlled trial. Contemp Clin Trials. 2006 Aug;27(4):353-63. Epub 2006 May 5.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andreas Obermair</name>
      <address>Queensland Centre for Gynaecological Cancer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>